Pharmacutical Gastric and Esophageal Cancer Drugs Market | Page 2

REPORT DESCRIPTION
Gastric and Esophageal Cancer Drugs Market – Overview
Gastric and esophageal cancers are characterized by growth of malignant (cancerous) cells, forming a
tumor, within the lining of stomach and esophagus. Smoking, excessive alcohol consumption, and Barrett’s
esophagus can causes gastric and esophageal cancers. Symptoms of gastric and esophageal cancers include
difficulty in swallowing (dysphagia), weight loss, chest pain, indigestion or heartburn, coughing or
hoarseness, pain behind the breastbone. Early stage of gastric and esophageal cancer does not show any of
this signs and symptoms.
Increasing number of cancer drugs in pipeline studies and rising involvement of key players for
development of cancer treatment are expected to propel gastric and esophageal cancer drugs market growth.
For instance, in April 2016, Centre Hospitalier Universitaire de Besancon, initiated Phase 1 and Phase 2
clinical trial for Carboplatin to determine the maximum tolerated dose (MTD) and recommended doses for
phase II (RP2D) by considering the treatment scheme of Dutch study for chemotherapy and radiotherapy.
The study is conducted in elderly patients with esophagus cancer. Carboplatin is an anticancer
chemotherapy drug from alkylating agent category. The study is estimated to complete by April 2024.
© Coherent market Insights. All Rights Reserved